For horses that respond to OSPHOS and manage their clinical advancement for 6 months, it is best to re-administer only when clinical indications recur. These values returned to standard by the subsequent evaluation, and were not associated with scientific indications of renal dysfunction. According to this info, FDA asked the corporation to i